Mark Leonard Singleton Sells 5,479 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of the firm’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $9.79, for a total value of $53,639.41. Following the completion of the transaction, the chief financial officer now owns 131,963 shares in the company, valued at $1,291,917.77. The trade was a 3.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62.

Bioventus Trading Down 3.3 %

Shares of BVS stock opened at $9.12 on Thursday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The company’s 50-day moving average price is $10.11 and its 200-day moving average price is $11.00. The stock has a market cap of $747.33 million, a price-to-earnings ratio of -14.95 and a beta of 0.86.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Hedge Funds Weigh In On Bioventus

Institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in shares of Bioventus by 38.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock valued at $4,662,000 after buying an additional 109,359 shares during the period. Point72 Asset Management L.P. acquired a new stake in Bioventus during the third quarter worth $788,000. JPMorgan Chase & Co. raised its position in Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock valued at $3,032,000 after purchasing an additional 176,442 shares during the period. State Street Corp lifted its stake in shares of Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Bioventus by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after purchasing an additional 65,374 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.